Luo D - Search Results

1

Novel ProTide prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of liver cancer.

Jiang L, Pan T, Lv Q, Yuan W, Liu X, Qu X, Luo D, Wan S, Cui S. Jiang L, et al. Among authors: luo d. Eur J Med Chem. 2023 Nov 15;260:115763. doi: 10.1016/j.ejmech.2023.115763. Epub 2023 Aug 25. Eur J Med Chem. 2023. PMID: 37659196

2

Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.

Luo D, Yi Y, Peng K, Liu T, Yang J, Liu S, Zhao W, Qu X, Yu W, Gu Y, Wan S. Luo D, et al. Eur J Med Chem. 2019 Sep 15;178:365-379. doi: 10.1016/j.ejmech.2019.06.006. Epub 2019 Jun 4. Eur J Med Chem. 2019. PMID: 31200238

3

S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer.

Zhang YH, Luo DD, Wan SB, Qu XJ. Zhang YH, et al. Pharmacol Res. 2020 May;155:104717. doi: 10.1016/j.phrs.2020.104717. Epub 2020 Feb 20. Pharmacol Res. 2020. PMID: 32088343

4

Corrigendum to "S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer" [Pharmacol Res. 155 (2020) 104717].

Zhang YH, Luo DD, Wan SB, Qu XJ. Zhang YH, et al. Pharmacol Res. 2020 Sep;159:104834. doi: 10.1016/j.phrs.2020.104834. Epub 2020 May 27. Pharmacol Res. 2020. PMID: 32473828 No abstract available.

5

SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.

Zhang YH, Shi WN, Wu SH, Miao RR, Sun SY, Luo DD, Wan SB, Guo ZK, Wang WY, Yu XF, Cui SX, Qu XJ. Zhang YH, et al. Oncogene. 2020 Jul;39(29):5214-5227. doi: 10.1038/s41388-020-1352-y. Epub 2020 Jun 16. Oncogene. 2020. PMID: 32546724

6

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.

Luo D, Zhang Y, Yang S, Tian X, Lv Y, Guo Z, Liu X, Han G, Liu S, Wang W, Cui S, Qu X, Wan S. Luo D, et al. Eur J Med Chem. 2021 Dec 5;225:113775. doi: 10.1016/j.ejmech.2021.113775. Epub 2021 Aug 12. Eur J Med Chem. 2021. PMID: 34411894

7

Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists.

Luo D, Guo Z, Zhao X, Wu L, Liu X, Zhang Y, Zhang Y, Deng Z, Qu X, Cui S, Wan S. Luo D, et al. Eur J Med Chem. 2022 Jan 5;227:113923. doi: 10.1016/j.ejmech.2021.113923. Epub 2021 Oct 15. Eur J Med Chem. 2022. PMID: 34688013

8

Structural modification of oridonin via DAST induced rearrangement.

Luo DD, Peng K, Yang JY, Piyachaturawat P, Saengsawang W, Ao L, Zhao WZ, Tang Y, Wan SB. Luo DD, et al. RSC Adv. 2018 Aug 20;8(52):29548-29554. doi: 10.1039/c8ra05728a. eCollection 2018 Aug 20. RSC Adv. 2018. PMID: 35547324 Free PMC article.

9

Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer.

Luo D, Liu X, Jiang L, Guo Z, Lv Y, Tian X, Wang X, Cui S, Wan S, Qu X, Xu X, Li X. Luo D, et al. J Med Chem. 2022 Nov 10;65(21):14553-14577. doi: 10.1021/acs.jmedchem.2c00958. Epub 2022 Oct 21. J Med Chem. 2022. PMID: 36269639

10

Correction to "Rational Design, Synthesis, and Biological Evaluation of Novel S1PR2 Antagonists for Reversing 5-FU-Resistance in Colorectal Cancer".

Luo D, Liu X, Jiang L, Guo Z, Lv Y, Tian X, Wang X, Cui S, Wan S, Xu X, Li X, Qu X. Luo D, et al. J Med Chem. 2022 Dec 8;65(23):15991. doi: 10.1021/acs.jmedchem.2c01832. Epub 2022 Nov 23. J Med Chem. 2022. PMID: 36417665 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,146 results

Search Page

Filters